Showing results (41-50 of 128) with videos related to

Sort By:
Pageof 13
The Journal of Thoracic and Cardiovascular Surgery|September 21, 2025
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancerDavid R Jones, Isabelle Opitz, David Harpole, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2013
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumorsL Rhoda Molife, Sarah M Rudman, Salma Alam, et al.
European Journal of Cancer (Oxford, England : 1990)|February 23, 2023
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 studyJürgen Wolf, Edward B Garon, Harry J M Groen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAF -mutant Solid TumorsRyan J Sullivan, Jeffrey Weber, Sapna Patel, et al.
BMC Cancer|October 25, 2024
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLCArmando Santoro, Garrido Pilar, Daniel S W Tan, et al.
The Oncologist|August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF AlterationsAditya Bardia, Mrinal Gounder, Jordi Rodon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and CeritinibJustin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
JCO Precision Oncology|January 27, 2022
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung CancersAlexander Drilon, Daniel S W Tan, Ulrik N Lassen, et al.
JTO Clinical and Research Reports|September 30, 2021
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup AnalysisDaniel S W Tan, Sarayut Geater, Chong-Jen Yu, et al.
Carcinogenesis|August 23, 2019
Circulating extracellular vesicle-associated TGFβ3 modulates response to cytotoxic therapy in head and neck squamous cell carcinomaDorival Mendes Rodrigues-Junior, Soon Sim Tan, Sai Kiang Lim, et al.
Pageof 13